| 
      
        | Patient    No | De    novo tumor | Liver    disease | Sex | IMS | Time    from OLT to malignancy (months) | Treatment | Outcome | Post-Tumor Follow-Up
 (months)
 |  
        | 1 | Esophagus | ALD | f | CyA | 57 | surgery | alive    nf | 122 |  
        | 2 | Esophagus | ALD | m | CyA | 49 | rt+ cht + palliation | died    nr | 13 |  
        | 3 | Esophagus | ALD | m | CyA | 84 | surgery    + rt + cht | alive    nf | 83 |  
        | 4 | Esophagus | ALD | m | FK | 66 | palliation | died    nr | 5 |  
        | 5 | Esophagus | ALD | m | CyA | 45 | palliation | died    nr | 15 |  
        | 6 | Neck | ALD | m | CyA | 146 | surgery | alive    nf | 18 |  
        | 7 | Larynx | ALD | f | CyA | 6 | surgery    + rt | died    nr | 139 |  
        | 8 | Salivary gland | ALD | m | CyA | 2 | surgery    + rt | alive    nf | 132 |  
        | 9 | Larynx | HCV/HBV | m | CyA | 98 | palliation | died    nr | 7 |  
        | 10 | Tongue | ALD | m | CyA | 19 | surgery | died    nr | 5 |  
        | 11 | Tongue | ALD | m | FK | 13 | surgery    + rt | alive    nf | 99 |  
        | 12 | Pharyngeal | ALD | f | CyA | 131 | palliation | died    nr | 1 |  
        | 13 | Stomach | ALD | m | CyA | 49 | surgery | died    nr | 4 |  
        | 14 | Stomach | HBV | m | FK | 77 | surgery    + rt + cht | alive    nf | 39 |  
        | 15 | Stomach | ALD | m | FK | 53 | surgery | died    nr | 1 |  
        | 16 | Lung | HCV/HBV | m | CyA | 133 | surgery | died    nr | 3 |  
        | 17 | Lung | PLD | m | FK | 13 | rt+cht | died    nr | 2 |  
        | 18 | Lung | PSC | m | FK | 34 | cht | died    nr | 29 |  
        | 19 | Lung | ALD | m | FK | 21 | cht | died    nr | 10 |  
        | 20 | Colon | HBV | m | CyA | 159 | surgery | died    nr | 10 |  
        | 21 | Colon | PSC-HCV | m | CyA | 133 | surgery    + cht | alive    nf | 30 |  
        | 22 | Melanoma | ALD | m | CyA | 97 | surgery | alive    nf | 20 |  
        | 23 | Melanoma | HCV/HBV | f | FK | 15 | surgery    + ifn | alive    nf | 71 |  
        | 24 | Cervix | ALD | f | CyA | 84 | surgery+rt | alive    nf | 84 |  
        | 25 | Cervix | HCV | f | CyA | 11 | surgery | died    nr | 16 |  
        | 26 | Breast | PBC | f | FK | 13 | surgery | alive    nf | 94 |  
        | 27 | Kaposi | hbv-hdv | m | CyA | 13 | surgery | died    nr | 54 |  
        | 28 | Kaposi | hbv | m | FK | 36 | surgery | died    nr | 93 |  
        | 29 | Kaposi | hbv | m | FK | 133 | surgery | alive    nf | 7 |  
        | 30 | Kaposi | SSC | m | CyA | 56 | surgery | died    nr | 40 |  
        | 31 | Kaposi | ALD | m | CyA | 5 | reduction    IMS | alive    wn | 108 |  
        | 32 | Kaposi | hcv | f | FK | 3 | surgery | alive    nf | 94 |  
        | 33 | PTLD | hbv | m | CyA | 72 | surgery    cht | died    nr | 64 |  
        | 34 | PTLD | PSC-hcv | f | CyA | 66 | surgery    cht | died    nr | 13 |  
        | 35 | PTLD | hcv | m | FK | 36 | cht | alive    nf | 32 |  
        | 36 | PTLD | HCV-HBV | m | FK | 58 | cht+rt | alive    nf | 44 |  
        | 37 | PTLD | HCV | m | FK | 101 | cht | died    nr | 3 |  
        | 38 | PTLD | HBV | m | CyA | 12 | cht+rituximab | alive    nf | 24 |  
        | 39 | PTLD | HCV | f | FK | 106 | cht | alive    nf | 16 |  
        | 40 | PTLD | HCV | m | FK | 80 | palliation | died    nr | 0 |  | 
  
    | ALD: Alcoholic Liver Disease; PSC: Primary Sclerosing Cholangitis; PBC: Primary Biliary Cirrhosis; PLD: Polycystic Liver Disease; SSC: Secondary Sclerosing Cholangitis;
nf: neoplsia free; nr: neoplasia related; wn: with neoplasia; cht: chemotherapy; rt: radiotherapy; IMS: Immunosuppression; PTLD: Post-Transplant Lymphoproliferative
Disease | 
  
    | Table 2: Clinical characteristics of the 40 patients with de novo tumor. |